Compound Granules of Hedyotis diffusa

PreclinicalSmall molecule

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Compound Granules of Hedyotis diffusa is one of 22 small molecule programs targeting Gastritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastritisActive, not recruiting

GastritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Gastritis

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

1 2

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

2 3

Nexium

DDexcel Pharma Technologies Ltd.

Approved

2 4

Takecab

PPhathom Pharmaceuticals, Inc.

Approved

1 5

Rabeprazole ER

Eisai

Approved

1 6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Mucosta

Biaxin

1 9

Entyvio

Takeda

Phase 2

1 10

Axid

Daewoong Pharmaceutical Co. LTD.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Gastritis

NCT07391800

Clinical

Trials by Indication[1]

Gastritis1 trial

Compound Granules of Hedyotis Diffusa for Chronic Atrophic Gastritis

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT07391800·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Compound Granules of Hedyotis diffusa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Compound Granules of Hedyotis diffusa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Compound Granules of Hedyotis diffusa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Compound Granules of Hedyotis diffusa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Gastritis1 trial

References

Drug Info

Quick Facts

Related News